Skip to main content

Table 1 Baseline characteristics of patients included in the study

From: Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

Characteristic Patients receiving 1LOT Patients receiving 2LOT Patients receiving 3LOT
Number of Patients 652 184 18
Centre
 Cambridge 228 (35.0%) 58 (31.5%) 5 (27.8%)
 Manchester 424 (65.0%) 126 (68.5%) 13 (72.2%)
Age at index, mean (SD) 64.84 (10.5) 62.97 (10.3) 65.06 (8.9)
  < 70 years, n (%) 424 (65.0%) 130 (70.7%) 13 (72.2%)
  ≥ 70 years, n (%) 228 (35.0%) 54 (29.4%) 5 (27.8%)
Male, n (%) 426 (65.3%) 124 (67.4%) 14 (77.8%)
Weight (kg), mean (SD) 78.12 (17.5) 79.99 (17.8) 77.92 (12.6)
 Missing, n (%) 243 (37.3%) 57 (31.0%) 6 (33.3%)
Histological subtype, n (%)
 Clear cell 518 (79.5%) 141 (76.6%) 13 (72.2%)
 Non-clear cell 70 (10.7%) 28 (15.2%) 4 (22.2%)
 Other 22 (3.4%) 5 (2.7%) 1 (5.6%)
MSKCC prognostic risk score (at time of LOT initiation), n(%)
 Favourable 73 (11.2%) 27 (14.7%) 2 (11.1%)
 Intermediate 380 (58.3%) 77 (41.9%) 11 (61.1%)
 Poor 174 (26.7%) 59 (32.1%) 2 (11.1%)
 Missing 25 (3.8%) 21 (11.4%)  
Ethnicity, n (%)
 White 629 (96.5%) 176 (95.7%) 17 (94.4%)
 Black 4 (0.6%) 2 (1.1%) 0 (0.0%)
 Asian (Chinese/other) 1 (0.2%) 1 (0.5%) 0 (0.0%)
 Asian (South-East Asian) 15 (2.3%) 5 (2.7%) 1 (5.6%)
 Mixed 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Other 3 (0.5%) 0 (0.0%) 0 (0.0%)
Comorbidity (History of), n (%)
 Hypertension 200 (30.7%) 55 (29.9%) 8 (44.4%)
 T1DM 5 (0.8%) 1 (0.5%) 0 (0.0%)
 T2DM 78 (12.0%) 27 (14.7%) 0 (0.0%)
 CAD 29 (4.5%) 4 (2.2%) 0 (0.0%)
 Congestive HF 4 (0.6%) 0 (0.0%) 0 (0.0%)
 Hypothyroidism 21 (3.2%) 6 (3.3%) 1 (5.6%)
 VTE 6 (0.9%) 1 (0.5%) 0 (0.0%)
 Autoimmune disease 1 (0.2%) 0 (0.0%) 0 (0.0%)
 Conditions involving regular corticosteroid therapy 5 (0.78%) 0 (0.0%) 0 (0.0%)
 Other 229 (35.1%) 62 (33.7%) 5 (27.8%)
  1. CAD Coronary Artery Disease, ECOG PS Eastern Cooperative Oncology Group Performance Status, HF Heart failure, MSKCC Memorial Sloan-Kettering Cancer Center, SD Standard deviation, T1DM Type 1 diabetes mellitus, T2DM Type 2 diabetes mellitus, VTE Venus Thromboembolism